CFB
LGND icon

Cullen/Frost Bankers’s Ligand Pharmaceuticals LGND Stock Holding History

Cullen/Frost Bankers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16
Closed -$2K – 1218
2021
Q1 		$2K Hold
16
– – ﹤0.01% 1024
2020
Q4 		$1K Hold
16
– – ﹤0.01% 1038
2020
Q3 		$1K Hold
16
– – ﹤0.01% 1098
2020
Q2 		$1K Hold
16
– – ﹤0.01% 1066
2020
Q1 		$1K Hold
16
– – ﹤0.01% 879
2019
Q4 		$1K Hold
16
– – ﹤0.01% 1017
2019
Q3 		$1K Hold
16
– – ﹤0.01% 980
2019
Q2 		$1K Hold
16
– – ﹤0.01% 992
2019
Q1 		$1K Buy
+16
New +$1.21K ﹤0.01% 894

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cullen/Frost Bankers's LGND Position: Q2 2021 in Review

Cullen/Frost Bankers sold out of Ligand Pharmaceuticals (LGND) in Q2 2021, closing a stake of 16 shares — an estimated $2K sold.

Cullen/Frost Bankers first reported a position in LGND in Q1 2019 and held it in 9 quarters. The position peaked at $2K in Q1 2021. 212 funds tracked by Wall St. Rank hold LGND as of Q2 2021.

  • Cullen/Frost Bankers reported no remaining Ligand Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cullen/Frost Bankers sold 16 Ligand Pharmaceuticals shares in Q2 2021, an estimated $2K.
  • Cullen/Frost Bankers first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Cullen/Frost Bankers's Ligand Pharmaceuticals position peaked at $2K in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2021.

Based on Cullen/Frost Bankers's 13F filing for Q2 2021, filed 5 Aug 2021.